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Abstract	
RNA	degradation	is	a	vital	post-transcriptional	process	which	ensures	that	transcripts	are	maintained	
at	 the	 correct	 level	 within	 the	 cell.	 DIS3L2	 and	 XRN1	 are	 conserved	 exoribonucleases	 which	 are	
critical	 for	 the	 degradation	 of	 cytoplasmic	 RNAs.	 Although	 the	 molecular	 mechanisms	 of	 RNA	
degradation	by	DIS3L2	and	XRN1	have	been	well	studied,	less	is	known	about	their	specific	roles	in	
development	 of	 multicellular	 organisms	 or	 human	 disease.	 This	 review	 focusses	 on	 the	 roles	 of	
DIS3L2	and	XRN1	in	the	pathogenesis	of	human	disease,	particularly	in	relation	to	phenotypes	seen	
in	model	 organisms.	 The	 known	 diseases	 associated	with	 loss	 of	 activity	 of	 DIS3L2	 and	 XRN1	 are	
discussed,	 together	 with	 possible	 mechanisms	 and	 cellular	 pathways	 leading	 to	 these	 disease	
conditions.			
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Introduction	
Ribonucleases	 are	 key	 enzymes	 involved	 in	 the	 control	 of	 mRNA	 stability,	 which	 is	 crucially	
important	in	maintaining	RNA	transcripts	at	the	correct	levels	within	cells.	Studies	have	shown	that	
40-50%	of	changes	 in	gene	expression	occur	at	the	level	of	RNA	stability	[1]	which	means	that	this	
process	 is	 highly	 important	 in	 regulating	 gene	 expression.	 In	 multi-cellular	 organisms,	 it	 is	
increasingly	evident	that	degradation	of	specific	mRNAs	is	critical	for	the	regulation	of	many	cellular	
processes,	 including	 early	 development,	 infection	 and	 inflammation,	 apoptosis,	 and	 ageing	 [2-7].	
Although	progress	has	been	made	in	identifying	the	targets	regulated	by	these	ribonucleases	[8-11],	
the	mechanisms	whereby	they	affect	cellular	processes	leading	to	disease	are	largely	unknown.	This	
review	focusses	on	two	highly	conserved	cytoplasmic	exoribonucleases,	DIS3L2	and	XRN1,	and	how	
dysregulation	 of	 these	 enzymes	 is	 implicated	 in	 human	 diseases.	 The	 association	 of	 the	 related	
exoribonuclease	DIS3	with	human	disease	has	recently	been	reviewed	elsewhere	[12].	
	 An	mRNA	 transcript	 is	 usually	 protected	 from	degradation	 by	 the	 5’	methylguanosine	 cap	
and	the	3’	poly-A	tail.	mRNAs	have	been	shown	to	be	held	in	a	circular	conformation	by	interactions	
of	 protein	 factors	 such	 as	 eIF4E	 (the	 cap-binding	 protein),	 eIF4G	 and	 the	 poly-A	 binding	 protein.	
Degradation	 usually	 begins	 with	 decircularisation	 of	 the	 RNA	 and	 the	 removal	 of	 the	 poly-A	 tail.	
Following	 this	process,	degradation	can	proceed	 in	 two	ways:	 	 in	 the	3’-5’	direction	or	 in	 the	5’-3’	
direction.	 In	 some	 circumstances	 (such	 as	 during	 nonsense-mediated	 decay	 or	 miRNA	 induced	
degradation),	 internal	 cleavage	occurs	prior	 to	degradation	of	 the	mRNA	 in	both	 the	3’-5’	 or	5’-3’	
directions	[2,	4,	5]	(Figure	1).		
	 During	3’-5’	degradation,	deadenylases	first	digest	away	the	poly-A	tail	leaving	an	exposed	3’	
end.	This	facilitates	3’-5’	degradation	by	a	family	of	ribonucleases	[9,	12],	including	DIS3	and	DIS3L2.	
DIS3L2	is	a	3'-5'	exoribonuclease	which	is	conserved	from	bacteria	to	humans.	It	acts	independently	
of	the	3'-5'	exoribonuclease-exosome	complex	and	degrades	non-coding	RNAs	as	well	as	mRNAs	[13,	
14].	 In	humans	and	the	yeast	S.	pombe,	 this	 is	often	achieved	by	addition	of	a	polyuridine	 (polyU)	
tract	 to	 the	 3'	 end	 of	 the	 transcript	 which	 provides	 an	 ideal	 landing	 pad	 for	 DIS3L2	 to	
initiate/reinitiate	3'-5'	decay	[14-16].	As	well	as	mRNAs,	miRNAs	such	as	pre-let-7	have	been	shown	
to	be	poly-uridylated	and	then	degraded	by	DIS3L2	in	human	cells	and	mouse	embryonic	stem	cells	
[17,	18].	
In	 contrast,	 there	 is	 only	 one	 known	 exoribonuclease	 involved	 in	 cytoplasmic	 5’-3’	
degradation;	 XRN1.	 After	 deadenylation	 by	 the	 Ccr4/Not	 deadenylase	 complex	 [19]	 the	 Lsm1-7	
complex	is	recruited	to	the	3'	end	of	the	RNA,	together	with	XRN1	and	decapping	proteins	such	as	
Dcp1	and	Dcp2	[20].	This	complex	activates	the	decapping	enzymes	which	cleave	off	the	5’	methyl-
guanosine	cap	allowing	the	threading	of	the	exposed	5’	end	through	to	the	active	site	of	XRN1	where	
it	 is	 digested.	Although	RNA	degradation	by	XRN1	 is	 likely	 to	be	 cotranslational	 [21],	 XRN1	 is	 also	
found	 in	 cytoplasmic	 foci,	 termed	 processing	 bodies	 (P-bodies)	 [22,	 23],	 which	 constitute	 a	
concentration	of	mRNA	decapping	machinery,	messenger	ribonucleoproteins	and	ribonucleases	[24].	
Here,	 mRNAs	 can	 also	 be	 stored	 for	 re-entry	 into	 translation	 at	 a	 later	 time.	 Being	 the	 only	
cytoplasmic	 exoribonuclease	 of	 its	 kind,	 this	 places	 XRN1	 at	 a	 pivotal	 position	 in	 the	 RNA	
degradation	pathway,	with	any	modulation	to	 this	enzyme	having	the	potential	 to	have	significant	
effects	on	cellular	function.		
Recent	work	using	human	tissue	culture	cells	and	model	organisms	shows	that	DIS3L2	and	
XRN1	 affect	 important	 cellular	 processes	 such	 as	 proliferation	 and	 apoptosis.	 Experiments	 using	
human	HeLa	 cells	 have	demonstrated	 that	 knockdown	of	DIS3L2	 results	 in	 increased	proliferation	
[25]	 and	 reduced	 apoptosis	 [16].	 Knockdown	 of	 DIS3L2	 in	 HeLa	 cells	 was	 also	 shown	 to	 result	 in	
mitotic	 errors	 and	affect	 the	expression	of	 key	 cell	 cycle	proteins	 including	Cyclin	D	and	Aurora	B	
kinase	[25],	suggesting	that	it	has	a	role	in	regulating	the	cell	cycle.	In	multicellular	organisms,	XRN1	
is	 involved	in	a	number	of	developmental	processes	[26,	27]	but	more	recently	has	been	shown	to	
be	a	key	player	in	controlling	apoptosis	[8,	9].	We	have	recently	demonstrated	that	null	mutations	in	
the	Drosophila	XRN1	homologue	pacman	result	in	wing	imaginal	discs	that	are	45%	the	size	of	wild-
type	controls	as	well	as	resulting	in	lethality	during	pupation.	Mutant	wing	discs	show	an	increase	in	
the	number	of	 cells	undergoing	apoptosis,	especially	 in	 the	wing	pouch	area.	The	pacman	mutant	
imaginal	discs	also	undergo	compensatory	proliferation,	but	this	is	not	sufficient	to	compensate	for	
the	 large	 amount	 of	 apoptosis	 occurring	 in	 these	 discs.	 The	 pro-apoptotic	 RNAs	 hid	 and	 reaper	
increase	 at	 the	 post-transcriptional	 level	 in	 pacman	 mutants,	 suggesting	 that	 they	 are	 targets	 of	
Pacman	 [8].	 Additionally,	 RNA-seq	 experiments	 have	 shown	 that	 a	 potential	 target	 of	 Pacman	 is	
dilp8,	a	Drosophila	 insulin-like	peptide	with	similarity	to	the	insulin-like	peptides	IGF-1	and	IGF-2	in	
humans	[9].	
Human	diseases	associated	with	DIS3L2	
	 The	clinical	importance	of	DIS3L2	is	demonstrated	by	its	association	with	Perlman	syndrome,	
which	 is	 a	 congenital	 overgrowth	 syndrome	 inherited	 in	 an	 autosomal	 recessive	 manner	 [28].	
Affected	 children	 display	 foetal	 gigantism,	 abnormal	 enlargement	 of	 organs	 (e.g.	 kidneys),	
macrocephaly,	 facial	 abnormalities,	 neurodevelopmental	 delay	 and	 high	 neonatal	 mortality.	
Histological	 examinations	 reveal	 nephroblastomatosis,	which	 is	 an	 important	 precursor	 for	Wilms’	
Tumour.	Germline	mutations	in	these	children	include	deletions	of	either	exon	6,	9	and/or	19	which	
are	consistent	with	a	loss	of	function	of	DIS3L2	[25,	29].			
	 Mutations	in	DIS3L2	have	also	been	associated	with	sporadic	occurrence	of	Wilms’	Tumour,	
a	kidney	cancer	also	referred	to	as	a	nephroblastoma	[25,	28,	29].	Wilms’	Tumour	results	from	the	
failure	 of	 groups	 of	 kidney	 cells	 to	 mature	 and	 differentiate,	 instead	 undergoing	 continuous	
proliferation.	 DIS3L2	 is	 also	 likely	 to	 be	 important	 in	 sporadic	 Wilms’	 Tumour	 as	 30%	 of	 these	
tumours	 (6/20)	 show	partial	 or	 complete	DIS3L2	 deletion	 [25].	 This	 tumour	 is	 not	 only	 associated	
with	aberrations	in	DIS3L2,	but	is	also	linked	to	mutations	in	the	DROSHA	gene,	leading	to	aberrant	
expression	of	oncogenic	miRNAs	[30],	such	as	miR-562	[31],	which	promotes	deregulation	of	EYA1.	
EYA1	 is	 involved	 in	 the	 retinal	 determination	 gene	network,	 and	has	been	associated	with	driving	
various	 malignancies	 (such	 as	 breast	 cancer)	 through	 the	 cell	 cycle,	 leading	 to	 extensive	
proliferation,	whilst	also	inhibiting	apoptosis	[32].	This	is	interesting	because	it	suggests	that	Wilms’	
Tumour	is	partially	driven	by	extensive	loss	of	the	RNA	degradation	machinery	itself,	highlighting	the	
importance	of	this	pathway.		
	 Other	 aberrations	 in	 the	DIS3L2	 gene	 have	 been	 associated	with	 a	Marfan-like	 syndrome	
with	 skeletal	 overgrowth	 [33].	 Three	 patients	 carrying	 a	 chromosomal	 translocation	 at	 the	
chromosomal	region	2q37.1	were	shown	to	have	a	breakpoint	within	the	DIS3L2	gene	at	intron	5	(2	
patients)	 and	 intron	 6	 (1	 patient)	 [33-35].	 The	 symptoms	 of	 these	 patients	 included	 skeletal	
overgrowth	 and	malformations,	 leading	 to	 long,	 slender	 fingers,	 curvature	 of	 the	 hands	 and	 feet	
(arachnodactyly),	lack	of	apoptosis	between	digits	(mild	syndactyly),	and	abnormal	curvature	of	the	
spine	(severe	scoliosis).	However,	 for	 these	patients,	 it	cannot	be	ruled	out	that	these	phenotypes	
are	 also	 affected	 by	 mis-expression	 of	 the	 neighbouring	 gene	NPPC	 (encoding	 C-type	 natriuretic	
peptide)	or	deletion	of	 the	gene	encoding	hsa-miR-562,	which	 is	 located	within	 intron	9	of	DIS3L2	
[33].	
Human	diseases	associated	with	XRN1	
	 Wilms’	 Tumour	 is	 not	 the	 only	 tumour	 which	 has	 been	 associated	 with	 defects	 in	 RNA	
degradation.	 Reduced	XRN1	mRNA	expression	has	been	demonstrated	 in	many	osteosarcoma	 cell	
lines	as	well	as	osteosarcoma	patient	samples	[36].	Osteosarcoma	is	the	third	most	common	cancer	
affecting	adolescents	with	a	second	smaller	peak	occurring	between	60	to	80	years,	particularly	 in	
people	affected	by	Paget’s	disease.	Overall,	osteosarcoma	has	a	moderate	incidence	rate,	with	10	to	
26	per	million	new	cases	worldwide	each	year	 [37].	Osteosarcoma	often	develops	at	either	end	of	
the	long	bones	of	the	arms	or	legs,	although	tumours	can	also	occur	in	the	skull	and	pelvis.	Tumours	
typically	arise	from	osteoid-producing	neoplastic	cells	adjacent	to	the	 long	bone	growth	plate.	The	
main	 cause	 of	 death	 in	 these	 patients	 is	 the	 spread	 of	 cancer	 cells	 to	 the	 lungs;	 these	 secondary	
tumours	are	present	in	10-20%	of	cases	at	diagnosis	[37].	
In	osteosarcoma	cells,	XRN1	 is	often	down-regulated,	suggesting	that	 lower	 levels	of	XRN1	
promote	 proliferation.	 However,	 null	 mutations	 and	 hypomorphic	 mutations	 of	 this	 conserved	
exoribonuclease	 in	Drosophila	 result	 in	apoptosis	[8].	This	apparent	contradiction	can	be	explained	
by	hypothesising	that	apoptosis	is	blocked	in	osteosarcoma	cells,	meaning	that	the	down-regulation	
of	XRN1	causes	an	increase	in	proliferation	of	the	tumour	cells	without	the	associated	apoptosis.	By	
this	 means,	 it	 may	 be	 that	 reduction	 of	 XRN1	 confers	 a	 growth	 advantage	 on	 the	 tumour	 cells.	
Alternatively,	downregulation	of	XRN1	may	lead	to	increased	expression	of	specific	miRNAs	and/or	
protein-coding	RNAs	which	then	promote	the	cancerous	phenotype.		Possible	candidates	are	IGF-1,	
which	is	known	to	induce	proliferation	of	osteoblasts	[38-40]	and/or	pro-inflammatory	RNAs	such	as	
FOS	and	MYC	which	are	widely	known	to	be	involved	in	cancer	progression.	
XRN1	and	the	host	response	to	viruses	
	 XRN1	also	appears	to	play	a	pivotal	role	during	the	host	response	to	viral	infection	and	has	
been	 implicated	 in	the	pathogenesis	of	a	number	of	viral	 families.	Recent	studies	have	shown	that	
the	activity	of	XRN1	is	specifically	inhibited	by	certain	Flaviviruses,	which	include	Dengue	fever	virus,	
West	 Nile	 virus	 [41],	 Yellow	 fever	 virus	 [42],	 Japanese	 Encephalitis	 virus	 [11]	 and,	 perhaps	 more	
notably	at	present,	the	Zika	virus.	Flaviviruses	are	single-stranded	(+)	sense	arthropod-borne	viruses	
which	 are	usually	 transmitted	 to	humans	 through	mosquitos	 but	 can	 also	be	 transmitted	 through	
ticks	[43].	Encephalitis	is	symptomatic	of	each	of	these	infections,	alongside	hemorrhagic fevers.	The	
activity	 of	 XRN1	 is	 also	 repressed	 in	 a	 similar	 manner	 by	 Hepatitis	 C	 (HCV)	 virus	 which	 primarily	
infects	the	liver,	and	can	lay	asymptomatic	for	many	years.	During	this	time,	the	virus	can	cause	liver	
scarring,	potentially	leading	to	cirrhosis,	liver	cancer	and	liver	failure	[44].	HCV,	along	with	Hepatitis	
B,	 has	 also	 been	 tenuously	 linked	 with	 pancreatic	 cancer	 and	 leukaemia/lymphoma	 [45-47].	 The	
targeting	of	XRN1	by	these	viruses	indicates	that	XRN1	is	normally	vitally	important	in	protecting	the	
cell	from	these	viral	pathogens.	
A	 series	 of	 recent	 publications	 have	 elucidated	 the	molecular	mechanisms	whereby	 these	
viruses	inhibit	XRN1	as	well	as	shedding	light	on	the	disease	mechanisms.	In	the	case	of	Dengue	and	
West	Nile	virus	(Kunjin	strain),	viral	transcripts	are	able	to	inhibit	the	5'-3'	RNA	degradation	pathway	
by	stalling	XRN1	within	the	3’	UTR	of	the	viral	RNA	(Figure	2A).	The	formation	of	RNA	pseudoknots	
("slipknots")	[48],	as	well	as		other	RNA	structures	within	the	3'UTR,	stall	the	progression	of	XRN1	by	
blocking	entry	of	the	RNA	into	the	active	site	[41].	XRN1	degrades	the	viral	RNAs	from	the	5’	end	of	
the	 transcript,	 until	 it	 reaches	 these	 structures,	 leaving	 small	 flaviviral	 non-coding	 RNAs	 (sfRNAs),	
which	accumulate	in	the	cytoplasm.	These	small,	structured	RNAs	bind	to	and	sequester	XRN1	thus	
reducing	5'-3'	degradation	of	other	cellular	RNAs	[49]	(Figure	2A).	For	HCV,	similar	highly	structured	
regions	within	the	5'UTRs	of	their	transcripts	stall	and	repress	the	activity	of	XRN1	(Figure	2B).	Using	
tissue	 culture	 cells	 infected	with	 HCV,	 it	 was	 shown	 that	 the	 disruption	 of	 the	 5’-3’	mRNA	 decay	
pathway	 results	 in	 stabilisation	 of	 short-lived	 RNAs	 such	 as	 transcription	 factors	 involved	 in	
oncogenesis	 (e.g.	MYC,	FOS	 and	 JUN)	 and	 angiogenesis	 (e.g.	VEGFA,	HIF1A	and	 CXCL2)	 [50].	 Since	
HCV	infection	is	associated	with	the	development	of	hepatocellular	carcinoma,	these	factors	might	
contribute	 to	 the	 development	 of	 the	 diseased	 state	 [49].	 This	 study	 also	 showed	 an	 increase	 in	
levels	of	capped	and	presumably	functional	RNAs	suggesting	that	repression	of	XRN1	leads	to	shut	
down	of	the	entire	degradation	pathway,	possibly	by	sequestration	of	other	decay	components	[50].	
In	 the	 case	 of	 Flaviviruses,	 the	 available	 evidence	 suggests	 that	 viral	 infection	 disproportionately	
affects	short-lived	transcripts	encoding	cytokines	and	factors	involved	in	innate	immunity	leading	to	
the	inflammatory	symptoms	observed	[49].	
The	 importance	of	XRN1	 in	 limiting	 the	pathogenesis	of	HCV	 is	 illustrated	by	 the	 fact	 that	
this	 virus	has	evolved	 two	ways	 to	 inhibit	 the	action	of	XRN1.	Recent	publications	 show	 that	5'-3'	
degradation	of	HCV	transcripts	is	stalled	by	expression	of	miR-122	in	the	host	cell,	which	binds	via	its	
miRNA	 seed	 sequence	 to	 the	 5'UTR	 of	 the	 viral	 transcript	 (Figure	 2C).	 The	 association	 of	miR-
122/RISC,	including	Ago2	[51],	at	two	sites	in	the	5’	UTR,	protects	it	from	degradation	by	XRN1	[52].	
miR-122	is	a	major	determinant	of	viral	RNA	replication,	as	it	inhibits	XRN1	from	degrading	the	viral	
RNA,	 allowing	 accumulation,	 increased	 replication,	 and	 increased	 translation	 of	 viral	 RNA.	 Studies	
have	shown	that	miR-122	only	needs	to	be	bound	at	one	of	the	two	sites	for	it	to	have	this	inhibitory	
effect,	 and	 binding	 to	 both	 sites	 maintains	 a	 co-operative	 effect,	 rather	 than	 increasing	 the	
effectiveness	 [52].	 In	 addition	 to	 the	miR-122	 binding	 site,	 the	 5'UTR	HCV	 viral	 RNA	 includes	 four	
stem	 loops	of	which	 three	 (loops	2-4)	 appear	 to	 function	as	a	highly	 structured	 internal	 ribosome	
entry	site,	allowing	 translation	 initiation	of	 the	viral	RNA	 [50].	Translation	of	 the	HCV	core	protein	
has	 been	 shown	 to	 activate	 the	 proto-oncogene,	MYC,	 allowing	 the	 progression	 of	 hepatocellular	
carcinomas	[53].	While	Loops	1	and	2	are	involved	in	viral	replication,	they	also	inhibit	the	activity	of	
XRN1	by	presenting	structures	which	stall	the	progress	of	XRN1	as	described	above.		
Another	way	in	which	viruses	can	inhibit	the	5'-3'	RNA	degradation	pathway	is	by	disruption	
of	P-bodies,	affecting	the	localisation	of	XRN1.	Rotavirus	infection	is	understood	to	disrupt	P-bodies,	
the	sites	of	concentration	of	the	RNA	degradation	machinery.	Rotavirus	is	an	RNA	virus	which	causes	
acute	diarrhoea	across	many	developing	countries,	mainly	affecting	young	children,	with	its	spread	
being	 attributable	 to	 poor	 sanitation	 and	 hygiene	 [54].	 This	 virus	 is	 a	 double-stranded,	 non-
enveloped	virus	which	utilises	rotavirus	protein	NSP1	to	degrade	the	deadenylase,	PAN3,	 in	 the	P-
bodies,	 resulting	 in	 transcript	 stabilisation,	 an	 effect	 also	 seen	 in	 Poliovirus	 [49].	 Rotavirus	 also	
causes	 the	 relocalisation	 of	 XRN1	 from	 the	 P-bodies	 to	 the	 nucleus,	 thereby	 inhibiting	 the	
degradation	 of	 viral	 RNA.	 However	 the	 molecular	 details	 of	 this	 are	 unknown.	 Viral	 proteins	
specifically	prevent	degradation	of	six	structural	transcripts	and	six	non-structural	transcripts,	which	
are	either	translated	into	protein,	or	serve	as	templates	for	replication	of	viral	progeny	[55].		
Concluding	remarks	
	 When	 DIS3L2	 and	 XRN1	 were	 first	 identified,	 it	 could	 not	 have	 been	 envisaged	 that	
investigation	of	these	apparent	'housekeeping"	exoribonucleases	would	lead	to	such	interesting	and	
fundamental	insights	into	the	molecular	mechanisms	of	RNA	decay.	As	described	above,	recent	work	
on	DIS3L2	and	XRN1	is	now	revealing	their	important	roles	in	cellular	function,	viability	and	human	
disease.	 Finding	 a	way	 to	 combat	disease	by	engineering	 the	RNA	degradation	machinery	 to	 alter	
patterns	of	RNA	regulation	observed	during	pathogenesis	offers	a	new	hope	to	many	people	in	the	
future.	This	is	especially	true	in	the	cancer	field.	For	example,	if	DIS3L2	or	XRN1	is	proven	to	facilitate	
overgrowth	 syndromes	 or	 the	 progression	 of	 osteosarcoma	 there	 is	 potential	 to	 develop	 novel	
therapies	for	these	diseases.	The	data	implicating	XRN1	as	a	key	enzyme	in	the	control	of	Flavivirus	
and	Hepatitis	C	viral	infection	also	presents	an	opportunity	for	the	development	of	broad	spectrum	
antiviral	 treatments.	 This	 is	 particularly	 important	 in	 the	wake	of	 new	viral	 epidemics	 such	 as	 the	
outbreak	of	the	Zika	virus	in	South	America.	It	is	clear	that	there	is	still	much	work	to	be	done	to	fully	
understand	 the	 ways	 in	 which	 DIS3L2	 and	 XRN1	 regulate	 cellular	 pathways	 resulting	 in	 disease	
progression.		A	good	starting	point	for	this	would	be	to	pinpoint	the	exact	RNA	transcripts	which	are	
being	 targeted	 by	 specific	 exoribonucleases	 in	 these	 pathways	 to	 elucidate	 how	 changes	 in	 RNA	
levels	could	contribute	to	pathogenesis.	From	starting	at	the	 level	of	basic	science,	this	could	have	
profound	implications	in	the	medical	world	in	the	future.		
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Figure	Legends:	
Figure	1:	Cartoon	depicting	deadenylation	dependent	RNA	degradation	pathways.	Bulk	eukaryotic	
mRNA	degradation	is	deadenylation	dependent,	which	is	predominantly	carried	out	by	the	Ccr4-Not	
complex.	 (A)	 Cleavage	 can	 occur	 during	 nonsense	 mediated	 decay	 or	 cleaved	 internally	 by	
endonucleases	 leaving	 unprotected	 3’	 and	 5’	 ends	 which	 can	 be	 degraded	 in	 either	 the	 5’	 or	 3’	
direction	by	XRN1	(5’)	or	the	exosome	complex	(3’).	(B)	Following	deadenylation	[56-58],	RNA		5'-3'	
degradation	 occurs,	 after	 the	 binding	 of	 the	 Lsm1/Pat1	 complex	 	 at	 the	 3'end	 activating	 the	
decapping	 complex.	 The	 unprotected	 5’	 ends	 are	 then	 degraded	 by	 XRN1.	 (C)	 Alternatively,	
degradation	can	occur	in	the	3'	-	5'	direction	by	the	exosome	complex,	of	which	the	catalytic	domain	
is	DIS3.	(D)	Deadenylated	mRNAs	can	also	be	uridylated	by	uridyl	transferases	(TUTases)	which	then	
target	the	RNA	for	degradation	by	the	exosome	independent	3'-5'	exoribonuclease	DIS3L2.		
Figure	2:	Inhibition	of	XRN1	in	the	5’	and	3’	UTRs	of	viral	transcripts.	(A)	XRN1	is	stalled	at	the	site	
of	 the	 Flaviviral	 3’	 UTR	 due	 to	 the	 presence	 of	 pseudoknots	 or	 stem	 loops.	 It	 is	 blocked	 from	
continuing	 degradation,	 allowing	 the	 accumulation	 of	 RNA	 secondary	 structures	 which	 constitute	
the	3’UTR	of	the	flaviviral	transcript.	(B)	XRN1	is	stalled	at	the	5’UTR	of	Hepatitis	C	viral	RNA	due	to	
the	 presence	 of	 stem	 loops	 and	 pseudoknots.	 In	 the	 case	 of	 A	 and	 B,	 XRN1	 is	 bound	 to	 and	
sequestered	by	these	strong	secondary	structures.	(C)	XRN1	is	stalled	at	the	5’	UTR	due	to	binding	of	
hsa-miR-122	 (green)	 at	 the	 seed	 sequence	 site	 and	 the	 presence	 of	 stem	 loops	 (1-4),	 during	HCV	
infection.		
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